Terbinafine Tablets

  • Fungal infections

Terbinafine Tablets Generic Name & Formulations

General Description

Terbinafine HCl 250mg.

Pharmacological Class

Allylamine antifungal.

How Supplied

Contact supplier

Terbinafine Tablets Indications


Onychomycosis of the toenail or fingernail due to tinea unguium.

Terbinafine Tablets Dosage and Administration


250mg once daily for 6 weeks (fingernail) or 12 weeks (toenail).


Not established.

Terbinafine Tablets Contraindications


Chronic or active liver disease.

Terbinafine Tablets Boxed Warnings

Not Applicable

Terbinafine Tablets Warnings/Precautions


Onychomycosis: confirm diagnosis with nail specimen. Perform LFTs prior to and periodically during treatment. Discontinue if hepatic injury, progressive skin rash (eg, Stevens-Johnson syndrome, toxic epidermal necrolysis, DRESS), taste/smell disturbances, severe neutropenia (neutrophils ≤1000 cells/mm3), thrombotic microangiopathy occur, or if lupus erythematosus is suspected. Monitor CBCs if immunodeficient. Renal impairment (CrCl <50mL/min). Pregnancy (Cat.B), nursing mothers: not recommended.

Terbinafine Tablets Pharmacokinetics

See Literature

Terbinafine Tablets Interactions


Antagonized by rifampin. May be potentiated by cimetidine or CYP2C9 and CYP3A4 inhibitors (eg, fluconazole, ketoconazole, amiodarone). May potentiate caffeine or drugs metabolized by CYP2D6 (eg, tricyclic antidepressants, SSRIs, beta-blockers). May antagonize cyclosporine.

Terbinafine Tablets Adverse Reactions

Adverse Reactions

Headache, diarrhea, rash, dyspepsia, liver enzyme abnormalities, pruritus, taste disturbances, nausea, abdominal pain, flatulence, urticaria; hepatotoxicity, depressive symptoms, smell disturbances.

Terbinafine Tablets Clinical Trials

See Literature

Terbinafine Tablets Note


Formerly known under the brand name Lamisil.

Terbinafine Tablets Patient Counseling

See Literature